.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Federal Trade Commission
Chubb
Colorcon
Moodys
US Department of Justice
QuintilesIMS
UBS
Merck
Chinese Patent Office

Generated: July 20, 2017

DrugPatentWatch Database Preview

DIABETA Drug Profile

« Back to Dashboard

Which patents cover Diabeta, and what generic Diabeta alternatives are available?

Diabeta is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in DIABETA is glyburide. There are twenty drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the glyburide profile page.

Summary for Tradename: DIABETA

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list7
Bulk Api Vendors: see list84
Clinical Trials: see list3
Patent Applications: see list5,609
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DIABETA at DailyMed

Pharmacology for Tradename: DIABETA

Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-001May 1, 1984AB2RXYesNo► Subscribe► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-002May 1, 1984AB2RXYesNo► Subscribe► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-003May 1, 1984AB2RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DIABETA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-003May 1, 19843,454,635► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-001May 1, 19844,060,634► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-002May 1, 19843,426,067► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-001May 1, 19843,426,067► Subscribe
Sanofi Aventis Us
DIABETA
glyburide
TABLET;ORAL017532-002May 1, 19843,454,635► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
QuintilesIMS
McKinsey
Deloitte
Medtronic
Mallinckrodt
Julphar
Colorcon
Chinese Patent Office
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot